Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
Atopic dermatitis
Comorbidities
Disease burden
Observational study
Treatment patterns
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
03
07
2023
accepted:
10
08
2023
medline:
30
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting. The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure. Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments. ClinicalTrials.gov identifier NCT03992417. Video Abstract.
Identifiants
pubmed: 37801232
doi: 10.1007/s12325-023-02644-5
pii: 10.1007/s12325-023-02644-5
pmc: PMC10611842
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Banques de données
ClinicalTrials.gov
['NCT03992417']
Types de publication
Observational Study
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5366-5382Informations de copyright
© 2023. The Author(s).
Références
Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75–91.
doi: 10.1111/ijd.14763
pubmed: 31930494
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.
doi: 10.1016/j.jaad.2017.04.019
pubmed: 28606711
Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73(3):696–704.
doi: 10.1111/all.13320
pubmed: 28960336
Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498–506.
doi: 10.1111/all.12112
pubmed: 23452057
Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.
doi: 10.2340/00015555-3510
pubmed: 32412646
Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327–34.
doi: 10.1016/j.det.2017.02.005
pubmed: 28577802
Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–68.
doi: 10.1111/exd.13911
pubmed: 30825336
pmcid: 6850480
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–37.
doi: 10.1080/1744666X.2017.1298443
pubmed: 28277826
Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and medical databases. Adv Ther. 2017;34(8):1989–2006.
doi: 10.1007/s12325-017-0582-z
pubmed: 28707285
pmcid: 5565673
de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–36.
doi: 10.1111/jdv.16003
pubmed: 31587373
pmcid: 7318704
Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111(14):5147–52.
doi: 10.1073/pnas.1323896111
pubmed: 24706858
pmcid: 3986150
Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153–8.
doi: 10.1073/pnas.1324022111
pubmed: 24706856
pmcid: 3986188
Dupilumab Prescribing Information. https://www.regeneron.com/downloads/dupixent_fpi.pdf . Accessed 13 Nov 2022.
Dupixent Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf . Accessed 13 Nov 2022.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–303.
doi: 10.1016/S0140-6736(17)31191-1
pubmed: 28478972
de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–101.
doi: 10.1111/bjd.16156
pubmed: 29193016
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.
doi: 10.1056/NEJMoa1610020
pubmed: 27690741
de Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164–73.
doi: 10.1080/09546634.2020.1866741
pubmed: 33461356
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–8.
doi: 10.1034/j.1600-0625.2001.100102.x
pubmed: 11168575
Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–9.
doi: 10.1159/000245677
pubmed: 9267730
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9.
doi: 10.1001/archderm.140.12.1513
pubmed: 15611432
Badia X, Mascaró JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141(4):698–702.
doi: 10.1046/j.1365-2133.1999.03112.x
pubmed: 10583119
Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–21.
doi: 10.1111/bjd.15641
pubmed: 28485036
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.
doi: 10.1111/bjd.13662
pubmed: 25580670
Vakharia PP, Chopra R, Sacotte R, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925–30.
doi: 10.1111/bjd.16078
pubmed: 29048751
pmcid: 5906166
Silverberg JI, Gelfand JM, Margolis DJ, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018;121(4):464-68.e3.
doi: 10.1016/j.anai.2018.07.004
pubmed: 30003968
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32.
doi: 10.1111/bjd.12590
pubmed: 24024631
pmcid: 3920642
Bagel J, Nguyen TQ, Lima H, et al. Baseline demographics and severity and burden of atopic dermatitis in adult patients initiating dupilumab treatment in a real-world registry (PROSE). Dermatol Ther (Heidelb). 2022;12(6):1417–30.
doi: 10.1007/s13555-022-00742-w
pubmed: 35590038
Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020;83(5):1375–84.
doi: 10.1016/j.jaad.2020.05.128
pubmed: 32485210
Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290–300.
doi: 10.1111/1346-8138.14787
pubmed: 30756423
pmcid: 6594225
Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, TREATgermany Study Group. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5:274–86.
doi: 10.5414/ALX02262E
pubmed: 34532636
pmcid: 8439109
Spekhorst LS, Ariëns LFM, van der Schaft, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Allergy. 2020;75(9):2376–9.
doi: 10.1111/all.14324
pubmed: 32302412
Thaçi D, Bauer A, von Kiedrowski R, et al. Dupilumab treatment of atopic dermatitis in routine clinical care: baseline characteristics of patients in the PROLEAD prospective, observational study. Dermatol Ther (Heidelb). 2022;12(9):2145–60.
doi: 10.1007/s13555-022-00791-1
pubmed: 35984627
Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212-23.e6.
doi: 10.1016/j.jaip.2020.12.059
pubmed: 33453450